Crescent Biopharma Inc. (CBIO)
NASDAQ: CBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CBIO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $543.21M
- EPS (TTM)
- -$7.29
- Dividend yield
- None
- Ex-dividend date
- Jan 13, 2023
- 52-week range
- 8.72 – 27.41
- Day range
- 12.53 – 13.30
- Volume / Avg
- 422.37K / 361.17K
- Beta
- —
- Shares outstanding
- 38.90M
52-week range
CBIO stock today
Shares of Crescent Biopharma (CBIO) finished higher on Nov 20 at $13.00, a gain of 0.70% or $0.09 per share, versus the S&P 500's 3.70% decline. Shares are 52.6% below their 52-week high of $27.41, set on Apr 22, 2026 and 49.1% above the 52-week low of $8.72, in the middle of the past year's range. CBIO is up 9.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 0.5%.
Crescent Biopharma has posted a net loss over the last twelve months (EPS of -$7.29), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Crescent Biopharma
Company profileCrescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Joshua T. Brumm
- Headquarters
- Waltham, MA
- Employees
- 80
- IPO year
- 2014
- Website
- crescentbiopharma.com
Financial highlights
Full financialsIn fiscal 2025, Crescent Biopharma generated $10.8 million in revenue. Crescent Biopharma reported a net loss of $153.9 million, compared with a loss of $37.9 million a year earlier. Operating margin was -1407.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $10.84M | — | $10.00K | $75.00K | $1.16M |
| Growth | — | — | -86.67% | -93.53% | -88.59% |
| Net income | $-153.94M | $-37.88M | $-36.90M | $-46.69M | $-63.43M |
| EPS (diluted) | — | $-0.59 | $-0.58 | $-0.89 | $-1.23 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$32.33+148.69%
- Strong buy 1
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-1.27 vs $-0.72
- Surprise
- -76.39%
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $24.00
- Ex-dividend date
- Jan 13, 2023
CBIO news
All CBIO news- Crescent Biopharma GAAP EPS of -$0.90Seeking Alpha
- Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswire
- Crescent Biopharma Announces Grants of Inducement AwardsGlobeNewswire
- Crescent Biopharma to Present at November Investor ConferencesGlobeNewswire
- Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001GlobeNewswire
Crescent Biopharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AVBPArriVent BioPharma Inc. | 10.52 | -6.57% | $544.13M | vs CBIO |
| ACRSAclaris Therapeutics Inc. | 3.44 | -1.71% | $545.63M | vs CBIO |
| CLYMClimb Bio Inc. | 9.19 | -0.97% | $539.80M | vs CBIO |
| ANLAdlai Nortye Group Ltd. ADR | 8.55 | -5.63% | $550.60M | vs CBIO |
| BCAXBicara Therapeutics Inc. | 8.44 | -7.46% | $560.31M | vs CBIO |
| GERNGeron Corporation | 0.8707 | -4.63% | $560.94M | vs CBIO |
| ZVRAZevra Therapeutics Inc. | 8.76 | -3.42% | $521.26M | vs CBIO |
| ALMSAlumis Inc. | 3.96 | -8.54% | $514.09M | vs CBIO |
Indexes, lists and sector
Crescent Biopharma stock FAQ
What is Crescent Biopharma's stock price today?
CBIO last traded at $13.00 as of Nov 20, 4:00 PM EST, up 0.70% on the day. Prices are delayed at least 15 minutes.
Does Crescent Biopharma pay a dividend?
Yes. Crescent Biopharma pays $0.00 per share annually. The most recent dividend of $24.00 had an ex-dividend date of Jan 13, 2023.
Who is Crescent Biopharma's CEO?
Mr. Joshua T. Brumm is the chief executive officer of Crescent Biopharma Inc., which has about 80 employees.
Has CBIO ever split its stock?
Yes. The most recent CBIO stock split was a 1-for-100 split on Jun 16, 2025.
What is the CBIO 52-week high?
The 52-week high for CBIO is $27.41 and the 52-week low is $8.72. The stock is currently 52.6% below its high.